Wordt geladen...
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
Epidermal growth factor receptor (EGFR) T790M mutation has shown to be associated with the clinical outcomes of patients after initial EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy in EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, its predictive role in EGFR-TKI re-challenge r...
Bewaard in:
Gepubliceerd in: | Oncotarget |
---|---|
Hoofdauteurs: | , , , , , , , , , , , , |
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
Impact Journals LLC
2016
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5354886/ https://ncbi.nlm.nih.gov/pubmed/27999211 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14007 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|